Short Course Radiotherapy Combined With Chemotherapy in Stage IV Rectal Cancer With Resectable Liver Metastases
研究概览
详细说明
Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks.
After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy.
研究类型
注册 (预期的)
阶段
- 阶段2
联系人和位置
学习地点
-
-
-
Beijing、中国、100021
- 招聘中
- Cancer Hospital, CAMS
-
接触：
- Hua Ren, attending
- 电话号码：87788122
- 邮箱：renhua2009@hotmail.com
-
接触：
- Jing Jin, professor
- 电话号码：87788200
- 邮箱：jingjin1025@163.com
-
-
Beijing
-
Beijing、Beijing、中国、100021
- 招聘中
- Dept of Radiation oncology, Cancer Hospital , Chinese Academy of Medical Science
-
首席研究员：
- jing jin, professor
-
接触：
- jing jin
- 电话号码：8610-87788280
- 邮箱：jingjin1025@163.com
-
接触：
- hua ren
- 电话号码：8610-87788122
- 邮箱：renhua2009@hotmail.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Histologically confirmed primary carcinoma of the rectum (Lower border of tumour ≤ 10 cm from anal verge) locally advanced stage in primary site of rectum resectable synchronous liver metastases. The decision of resectable liver metastases will be made at multidisciplinary clinical meetings.
Exclusion Criteria:
- Obstruction of the gastrointestinal tract Previously constructed stoma prior radiotherapy of the pelvis
学习计划
研究是如何设计的？
设计细节
- 主要用途：治疗
- 分配：不适用
- 介入模型：单组作业
- 屏蔽：无（打开标签）
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的：Short course radiotherapy
Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks. After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy. |
Patients with rectal cancer and resectable liver metastases receive 25 Gy in 5 fractions of 5 Gy over 5 days to the pelvis and XELOX consolidating chemotherapy (with or without target therapy) al least 4 cycles after 2 weeks. After evaluation, patients with resectable rectal cancer and liver metastasis will undergo surgery. Those patients with unresectable lesions will receive chemotherapy. |
研究衡量的是什么？
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
percentage of patients undergo R0 surgery during the follow-up
大体时间：3 months
|
3 months
|
次要结果测量
结果测量 |
大体时间 |
|---|---|
|
The rate of early toxicity of radiotherapy according to the NCI Common Toxicity Criteria for Adverse Effects (version 3.0)
大体时间：3 months
|
3 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.